Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome
| Autor: | Diana Andrea Herrera-Sánchez, Laura Berrón-Ruiz, Fernando Lozano-Patiño, Leopoldo Santos-Argumedo, Sagrario Hierro-Orozco, Cesar Daniel Alonso-Bello, María Isabel Castrejón-Vázquez, María Eugenia Vargas-Camaño, Julio César Alcántara-Montiel, Mario Alberto Ynga-Durand, Maria C. Jiménez-Martínez |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
lcsh:Immunologic diseases. Allergy
0301 basic medicine medicine.drug_class Immunology Efalizumab Connective tissue Case Report Omalizumab Immunoglobulin E Monoclonal antibody medicine.disease_cause 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine medicine Immunology and Allergy biology business.industry medicine.disease 030104 developmental biology medicine.anatomical_structure Staphylococcus aureus biology.protein Primary immunodeficiency Eczematous dermatitis lcsh:RC581-607 business medicine.drug |
| Zdroj: | Case Reports in Immunology Case Reports in Immunology, Vol 2019 (2019) |
| ISSN: | 2090-6617 2090-6609 |
| Popis: | Hyper-IgE syndrome (HIES) is a rare primary immunodeficiency characterized by elevated levels of immunoglobulin E (IgE), eczematous dermatitis, cold abscesses, and recurrent infections of the lung and skin caused by Staphylococcus aureus. The dominant form is characterized by nonimmunologic features including skeletal, connective tissue, and pulmonary abnormalities in addition to recurrent infections and eczema. Omalizumab is a humanized recombinant monoclonal antibody against IgE. Several studies reported clinical improvement with omalizumab in patients with severe atopic eczema with high serum IgE level. We present the case of a 37-year-old male with HIES and cutaneous manifestations, treated with humanized recombinant monoclonal antibodies efalizumab and omalizumab. After therapy for 4 years, we observed diminished eczema and serum IgE levels. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |